Learn how WARF Therapeutics (WT), launched in 2018, is translating scientific discoveries at University of Wisconsin-Madison into therapeutics through a unique and innovative model. Jonathan Young will share details of the latest Pre-Clinical Development Candidate, a best in class Carbonic Anhydrase 9 (CA9) radiopharmaceutical, for clear cell renal cell carcinoma (ccRCC).
Our guest speaker, Jonathan Young, who helped bring WARFs (Wisconsin Alumni Research Foundation) vision to life, structured this initiative aimed to offer a flexible, cost-effective drug discovery pipeline while engaging UW researchers and aligning with UW-Madison leadership.
With his 20+ years as a medicinal chemist in pharma and biotech, Jon walks the hallways of the research labs as a “drug hunter” looking for potential targets to drug. He works closely with his lean team and scientific advisory committee to identify, derisk and push forward select programs.
Learn what key elements matter to his team, the process by which drugs move along the pipeline, and how they've created a win for translationally minded researchers, WT, university, and patients alike.
This event is co-hosted by the Querrey InQbation Lab and Lurie Cancer Center.
Sonia Kim
(847) 467-0446
Email